Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Payables (2018 - 2025)

AVITA Medical's Payables history spans 8 years, with the latest figure at $9.0 million for Q4 2025.

  • For Q4 2025, Payables rose 42.34% year-over-year to $9.0 million; the TTM value through Dec 2025 reached $9.0 million, up 42.34%, while the annual FY2025 figure was $9.0 million, 42.34% up from the prior year.
  • Payables reached $9.0 million in Q4 2025 per RCEL's latest filing, up from $8.1 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $9.0 million in Q4 2025 to a low of $2.4 million in Q1 2022.
  • Average Payables over 5 years is $4.5 million, with a median of $3.8 million recorded in 2023.
  • Peak YoY movement for Payables: tumbled 34.11% in 2022, then skyrocketed 93.81% in 2025.
  • A 5-year view of Payables shows it stood at $2.7 million in 2021, then rose by 10.86% to $3.0 million in 2022, then rose by 26.35% to $3.8 million in 2023, then skyrocketed by 65.94% to $6.3 million in 2024, then surged by 42.34% to $9.0 million in 2025.
  • Per Business Quant, the three most recent readings for RCEL's Payables are $9.0 million (Q4 2025), $8.1 million (Q3 2025), and $7.3 million (Q2 2025).